AstraZeneca Plc and Daiichi Sankyo Co. are challenging Gilead Sciences Inc. for dominance in one of the toughest-to-treat breast cancers, with new data from Europe’s biggest oncology meeting signaling ...

Retail buzz spiked around Gilead Sciences Inc. after the biotech firm on Sunday revealed new data showing that its cancer ...

Gilead Sciences' Trodelvy lowered the risk of disease progression in an aggressive type of breast cancer by 38% when used as ...

AstraZeneca and Gilead both reported successful trials in a hard-to-treat form of breast cancer, sparking a debate about ...

Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek ...

Gilead Sciences (GILD) is drawing attention this week as it presents new clinical results at both the European AIDS ...

Discover why Gilead Sciences (GILD) is a top healthcare stock in 2025 with strong fundamentals and growth potential.

Susan Galbraith, Ph.D., AZ’s oncology R&D chief, attributed Datroway’s strong efficacy to its ADC construct, specifically its ...

Gilead Sciences and Arcus Biosciences’ anti-TIGIT antibody domvanalimab has been tied to median overall survival of close to ...

Gilead Sciences settled patent disputes with Lupin, Cipla, and Laurus, delaying U.S. generic entry of HIV drug Biktarvy until April 2036.

The biopharma will aim to bolster its pipeline, with plans to present updated results for novel long-acting combination ...

GSK’s ViiV Healthcare and its bimonthly pre-exposure prophylaxis (PrEP) medicine Apretude had to make room for another long-acting PrEP option this summer, when rival Gilead Sciences rolled out Yez | ...